Progesterone is not the same as 17α-hydroxyprogesterone caproate: Implications for obstetrical practice

American Journal of Obstetrics and Gynecology

Volumn 208, Issue 6, 2013, Pages 421-426

  Romero, Roberto ^a   Stanczyk, Frank Z ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; HEXANOIC ACID; HYDROXYPROGESTERONE CAPROATE; MIFEPRISTONE; PLACEBO; PROGESTERONE;

CLINICAL PRACTICE; DRUG SAFETY; GENE EXPRESSION; HUMAN; MORTALITY; PLACENTA; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; UPREGULATION; UTERINE CERVIX RIPENING;

EID: 84878390886     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2013.04.027     Document Type: Editorial

References (80)

1. P.J. Meis, M. Klebanoff, E. Thom Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385
2. A.T. Tita, D.J. Rouse Progesterone for preterm birth prevention: an evolving intervention Am J Obstet Gynecol 200 2009 219 224
3. A. Sotiriadis, S. Papatheodorou, G. Makrydimas Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis Ultrasound Obstet Gynecol 40 2012 257 266
4. V.M. Schmouder, G.M. Prescott, A. Franco, P. Fan-Havard The rebirth of progesterone in the prevention of preterm labor Ann Pharmacothe 47 2013 527 536
5. American College of Obstetricians and Gynecologists ACOG committee opinion no. 419: use of progesterone to reduce preterm birth Obstet Gynecol 112 2008 963 965
6. American College of Obstetricians and Gynecologists ACOG practice bulletin no. 130: prediction and prevention of preterm birth Obstet Gynecol 120 2012 964 973
7. D. Farine, W.R. Mundle, J. Dodd The use of progesterone for prevention of preterm birth J Obstet Gynaecol Can 30 2008 67 77
8. S.N. Caritis, S. Sharma, R. Venkataramanan Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation Am J Obstet Gynecol 205 2011 40.e1 40.e8
9. S.N. Caritis, S. Sharma, R. Venkataramanan Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation Am J Obstet Gynecol 207 2012 398.e1 398.e8
10. F.Z. Stanczyk, J.P. Hapgood, S. Winer, D.R. Mishell Jr Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects Endocr Rev 34 2013 171 208
11. F.Z. Stanczyk All progestins are not created equal Steroids 68 2003 879 890
12. A.E. Schindler, C. Campagnoli, R. Druckmann Classification and pharmacology of progestins Maturitas 61 2008 171 180
13. North American Menopause Society Role of progestogen in hormone therapy for postmenopausal women: position statement of the North American Menopause Society Menopause 10 2003 113 132
14. A.I. Csapo, E. Knobil, H.J. van der Molen, W.G. Wiest Peripheral plasma progesterone levels during human pregnancy and labor Am J Obstet Gynecol 110 1971 630 632
15. A.I. Csapo, M.O. Pulkkinen, B. Ruttner, J.P. Sauvage, W.G. Wiest The significance of the human corpus luteum in pregnancy maintenance: I, preliminary studies Am J Obstet Gynecol 112 1972 1061 1067
16. A.I. Csapo, M.O. Pulkkinen, H.L. Kaihola The effect of luteectomy-induced progesterone-withdrawal on the oxytocin and prostaglandin response of the first trimester pregnant human uterus Prostaglandins 4 1973 421 429
17. A.I. Csapo, T. Erdos The critical control of progesterone levels and pregnancy by antiprogesterone Am J Obstet Gynecol 126 1976 598 601
18. A.I. Csapo, T. Erdos Prevention of the abortifacient action of antiprogesterone serum by progesterone Am J Obstet Gynecol 128 1977 212 214
19. T. Kerenyi Forgotten "father of progesterone." Am J Obstet Gynecol 202 2010 e10 e11
20. L. Kovacs, M. Sas, B.A. Resch Termination of very early pregnancy by RU 486: an antiprogestational compound Contraception 29 1984 399 410
21. A.A. Haspels Interruption of early pregnancy by an anti-progestational compound, RU 486 Eur J Obstet Gynecol Reprod Biol 20 1985 169 175
22. E.E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science 245 1989 1351 1357
23. E.E. Baulieu The Albert Lasker Medical Awards RU-486 as an antiprogesterone steroid: from receptor to contragestion and beyond JAMA 262 1989 1808 1814
24. R. Frydman, C. Lelaidier, C. Baton-Saint-Mleux, H. Fernandez, M. Vial, P. Bourget Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study Obstet Gynecol 80 1992 972 975
25. R. Frydman, S. Taylor, C. Paoli, A. Pourade [RU 486 (mifepristone): a new tool for labor induction women at term with live fetus] Contracept Fertil Sex (Paris) 20 1992 1133 1136
26. C. Lelaidier, C. Baton, J.L. Benifla, H. Fernandez, P. Bourget, R. Frydman Mifepristone for labour induction after previous caesarean section BJOG 101 1994 501 503
27. C. Lelaidier, J.L. Benifla, H. Fernandez [The value of RU-486 (mifepristone) in medical indications of the induction of labor at term Results of a double-blind randomized prospective study (RU-486 versus placebo)] J Gynecol Obstet Biol Reprod (Paris) 22 1993 91 100
28. B.J. Attardi, A. Zeleznik, H. Simhan, J.P. Chiao, D.R. Mattison, S.N. Caritis Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins Am J Obstet Gynecol 197 2007 599.e1 599.e7
29. T.R. Varma, J. Morsman Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy Int J Gynaecol Obstet 20 1982 13 17
30. E.B. Da Fonseca, R.E. Bittar, R. Damiao, M. Zugaib Prematurity prevention: the role of progesterone Curr Opin Obstet Gynecol 21 2009 142 147
31. L.W. Doyle Antenatal progesterone to prevent preterm birth Lancet 373 2009 2000 2002
32. N.R. Hall What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Obstet Gynecol Clin North Am 38 2011 235 246 ix-x
33. E.R. Norwitz, A.B. Caughey Progesterone supplementation and the prevention of preterm birth Rev Obstet Gynecol 4 2011 60 72
34. D.J. Rouse, S.N. Caritis, A.M. Peaceman A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins N Engl J Med 357 2007 454 461
35. C. Nold, M. Maubert, L. Anton, S. Yellon, M.A. Elovitz Prevention of preterm birth by progestational agents: what are the molecular mechanisms? Am J Obstet Gynecol 208 2013 223.e1 223.e7
36. M.V. Senat, R. Porcher, N. Winer Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial Am J Obstet Gynecol 208 2013 194.e1 194.e8
37. T. Manuck, M. Kamyar, M.S. Esplin, R. Silver, T.F. Porter, M. Varner Cervical cerclage, progesterone supplementation, and spontaneous preterm birth Am J Obstet Gynecol 208 suppl 2013 S226
38. S. Ibrahim, C.D. Lynch, H. Walker, K. Rodewald, J.D. Iams Effect of 17-alpha-hydroxyprogesterone caproate injections on rate of cervical length change in women with a history of prior preterm birth Am J Obstet Gynecol 208 suppl 2013 S225
39. L. Temming, C.T. Kirkland, S. Kullstam, N. Rozario, A. Mitra, S. Joy A retrospective comparison of cerclage alone vs cerclage and 17P for the prevention of preterm birth Am J Obstet Gynecol 208 suppl 2013 S219
40. T. Manuck, S. Watkins, M.S. Esplin, M. Jackson, L. Jorde, M. Varner Next generation sequencing identifies the IL-12 receptor beta gene as a potential mediator in the response to 17-alpha-hydroxyprogesterone caproate for the prevention of recurrent prematurity Am J Obstet Gynecol 208 suppl 2013 S227
41. N.K. Ruddock, S.Q. Shi, S. Jain Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions Am J Obstet Gynecol 199 2008 391.e1 391.e7
42. 17P. Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/17P Accessed May 2, 2013
43. Hydroxyprogesterone. Pharmacy and OB/Gyn Clinic, The Ohio State University Medical Center https://patienteducation.osumc.edu/Documents/ Hydroxyprogesterone.pdf Accessed May 2, 2013
44. Gestiva slides revision. Meeting of the Advisory Committee for Reproductive Health Drugs, Aug. 29, 2006 NDA 21-945, 17α- hydroxyprogesterone caproate (Gestiva) http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4227S1-02-03-FDA-Wesley-files/frame.htm Accessed May 2, 2013
45. D.J. Sexton, M.W. O'Reilly, A.M. Friel, J.J. Morrison Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro Reprod Biol Endocrinol 2 2004 80
46. L. Anderson, W. Martin, C. Higgins, S.M. Nelson, J.E. Norman The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy Reprod Sci 16 2009 1052 1061
47. R.J. Kuon, S.Q. Shi, H. Maul Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle Am J Obstet Gynecol 202 2010 455.e1 455.e9
48. H.A. Rodriguez, L. Kass, J. Varayoud Collagen remodelling in the guinea-pig uterine cervix at term is associated with a decrease in progesterone receptor expression Mol Hum Reprod 9 2003 807 813
49. R.E. Garfield, G. Saade, C. Buhimschi Control and assessment of the uterus and cervix during pregnancy and labour Hum Reprod Update 4 1998 673 695
50. K. Imada, A. Ito, T. Sato, M. Namiki, H. Nagase, Y. Mori Hormonal regulation of matrix metalloproteinase 9/gelatinase B gene expression in rabbit uterine cervical fibroblasts Biol Reprod 56 1997 575 580
51. C. Hegele-Hartung, K. Chwalisz, H.M. Beier, W. Elger Ripening of the uterine cervix of the guinea-pig after treatment with the progesterone antagonist onapristone (ZK 98.299): an electron microscopic study Hum Reprod 4 1989 369 377
52. R.A. Word, X.H. Li, M. Hnat, K. Carrick Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts Semin Reprod Med 25 2007 69 79
53. S. Andersson, D. Minjarez, N.P. Yost, R.A. Word Estrogen and progesterone metabolism in the cervix during pregnancy and parturition J Clin Endocrinol Metab 93 2008 2366 2374
54. R. Romero Clinical application of nitric oxide donors and blockers Hum Reprod 13 1998 248 250
55. H. Xu, J.M. Gonzalez, E. Ofori, M.A. Elovitz Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth? Am J Obstet Gynecol 198 2008 314.e1 314.e8
56. K. Chwalisz The use of progesterone antagonists for cervical ripening and as an adjunct to labour and delivery Hum Reprod 9 suppl 1 1994 131 161
57. A. Ito, K. Imada, T. Sato, T. Kubo, K. Matsushima, Y. Mori Suppression of interleukin 8 production by progesterone in rabbit uterine cervix Biochem J 301 1994 183 186
58. Y. Stjernholm, L. Sahlin, S. Akerberg Cervical ripening in humans: potential roles of estrogen, progesterone, and insulin-like growth factor-I Am J Obstet Gynecol 174 1996 1065 1071
59. R. Holt, B.C. Timmons, Y. Akgul, M.L. Akins, M. Mahendroo The molecular mechanisms of cervical ripening differ between term and preterm birth Endocrinology 152 2011 1036 1046
60. S.M. Yellon, A.E. Burns, J.L. See, T.J. Lechuga, M.A. Kirby Progesterone withdrawal promotes remodeling processes in the nonpregnant mouse cervix Biol Reprod 81 2009 1 6
61. F. Facchinetti, S. Paganelli, G. Comitini, G. Dante, A. Volpe Cervical length changes during preterm cervical ripening: effects of 17-alpha- hydroxyprogesterone caproate Am J Obstet Gynecol 196 2007 453.e1 453.e4 discussion 421
62. K.J. Straach, J.M. Shelton, J.A. Richardson, V.C. Hascall, M.S. Mahendroo Regulation of hyaluronan expression during cervical ripening Glycobiology 15 2005 55 65
63. S.M. Yellon, B.T. Oshiro, T.Y. Chhaya Remodeling of the cervix and parturition in mice lacking the progesterone receptor B isoform Biol Reprod 85 2011 498 502
64. K. Clark, H. Ji, H. Feltovich, J. Janowski, C. Carroll, E.K. Chien Mifepristone-induced cervical ripening: structural, biomechanical, and molecular events Am J Obstet Gynecol 194 2006 1391 1398
65. J.M. Gonzalez, C.W. Franzke, F. Yang, R. Romero, G. Girardi Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice Am J Pathol 179 2011 838 849
66. J.M. Gonzalez, R. Romero, G. Girardi Comparison of the mechanisms responsible for cervical remodeling in preterm and term labor J Reprod Immunol 97 2013 112 119
67. C.P. Durnwald, C.D. Lynch, H. Walker, J.D. Iams The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time Am J Obstet Gynecol 201 2009 410.e1 410.e5
68. J.M. O'Brien, E.A. Defranco, C.D. Adair Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial Ultrasound Obstet Gynecol 34 2009 653 659
69. M.J. Keirse Progesterone and preterm: seventy years of "deja vu" or "still to be seen"? Birth 31 2004 230 235
70. J.D. Iams Was the preterm birth rate in the placebo group too high in the Meis MFMU Network trial of 17-OHPC? Am J Obstet Gynecol 202 2010 409 410
71. R. Romero, L. Yeo, J. Miranda, S.S. Hassan, A. Conde-Agudelo, T. Chaiworapongsa A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix J Perinat Med 41 2013 27 44
72. E.B. Fonseca, E. Celik, M. Parra, M. Singh, K.H. Nicolaides Progesterone and the risk of preterm birth among women with a short cervix N Engl J Med 357 2007 462 469
73. S.S. Hassan, R. Romero, D. Vidyadhari Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial Ultrasound Obstet Gynecol 38 2011 18 31
74. R. Romero, K. Nicolaides, A. Conde-Agudelo Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data Am J Obstet Gynecol 206 2012 124.e1 124.e19
75. W.A. Grobman, E.A. Thom, C.Y. Spong 17 Alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm Am J Obstet Gynecol 207 2012 390.e1 390.e8
76. J.M. O'Brien, J.J. Steichen, J.A. Phillips, G.W. Creasy Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebo-controlled trial Am J Obstet Gynecol 206 suppl 2012 S223
77. A. Rebarber, N.B. Istwan, K. Russo-Stieglitz Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery Diabetes Care 30 2007 2277 2280
78. T.P. Waters, B.A. Schultz, B.M. Mercer, P.M. Catalano Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy Obstet Gynecol 114 2009 45 49
79. C. Gyamfi, A.L. Horton, V. Momirova The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies Am J Obstet Gynecol 201 2009 392.e1 392.e5
80. C.A. Combs, T. Garite, K. Maurel, A. Das, M. Porto Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial Am J Obstet Gynecol 203 2010 248.e1 248.e9